business.financialpost.com
Acerus Announces Initiation of a Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil
TORONTO — Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP) today announced first dosing of subjects in a Phase 1 clinical trial testing a proprietary intranasal formulation …